Clinical observations on the therapeutic activity of flupentixol in the treatment of chronic schizophrenia.
D000328:Adult; D000368:Aged; D001769:Blood / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002746:Chlorpromazine / Q000627:therapeutic use; D002908:Chronic Disease; D003702:Delusions / Q000188:drug therapy; D003864:Depression, Chemical; D005260:Female; D006212:Hallucinations / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009966:Orphenadrine / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010879:Piperazines / Q000627:therapeutic use; D011596:Psychomotor Disorders / Q000188:drug therapy; D011600:Psychopharmacology; D012559:Schizophrenia / Q000188:drug therapy*; D012919:Social Behavior / Q000187:drug effects; D013268:Stimulation, Chemical; D000637:Transaminases / Q000097:blood; D014966:Xanthenes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D006993:Hypnotics and Sedatives; D010879:Piperazines; D014966:Xanthenes; D009966:Orphenadrine; D000637:Transaminases; D002746:Chlorpromazine